Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

197 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Bevacizumab + capecitabine as maintenance therapy after initial bevacizumab + XELOX treatment in previously untreated patients with metastatic colorectal cancer: phase III 'Stop and Go' study results--a Turkish Oncology Group Trial.
Yalcin S, Uslu R, Dane F, Yilmaz U, Zengin N, Buyukunal E, Buyukberber S, Camci C, Sencan O, Kilickap S, Ozdener F, Cevik D. Yalcin S, et al. Among authors: buyukberber s. Oncology. 2013;85(6):328-35. doi: 10.1159/000355914. Epub 2013 Nov 12. Oncology. 2013. PMID: 24247559 Free article. Clinical Trial.
Bevacizumab every 4 weeks is as effective as every 2 weeks in combination with biweekly FOLFIRI in metastatic colorectal cancer.
Yildiz R, Benekli M, Ozkan M, Alkis N, Berk V, Kaplan MA, Ciltas A, Karaca H, Durnali AG, Coskun U, Dikilitas M, Sevinc A, Dane F, Yetisyigit T, Dogu GG, Buyukberber S. Yildiz R, et al. Among authors: buyukberber s. J Cancer Res Clin Oncol. 2012 Nov;138(11):1845-52. doi: 10.1007/s00432-012-1264-5. Epub 2012 Jun 22. J Cancer Res Clin Oncol. 2012. PMID: 22722713
Adjuvant systemic chemotherapy with or without bevacizumab in patients with resected liver metastases from colorectal cancer.
Turan N, Benekli M, Koca D, Ustaalioglu BO, Dane F, Ozdemir N, Ulas A, Oztop I, Gumus M, Ozturk MA, Berk V, Kucukoner M, Uner A, Balakan O, Helvaci K, Ozkan S, Yilmaz U, Buyukberber S; Anatolian Society of Medical Oncology. Turan N, et al. Among authors: buyukberber s. Oncology. 2013;84(1):14-21. doi: 10.1159/000342429. Epub 2012 Oct 16. Oncology. 2013. PMID: 23076023
Results of adjuvant FOLFOX regimens in stage III colorectal cancer patients: retrospective analysis of 667 patients.
Uncu D, Aksoy S, Çetin B, Yetişyiğit T, Özdemir N, Berk V, Dane F, Inal A, Harputluoğlu H, Budakoğlu B, Koca D, Sevinç A, Cihan S, Durnalı AG, Özkan M, Öztürk MA, Işıkdoğan A, Büyükberber S, Benekli M, Köş T, Alkış N, Karaca H, Turhal NS, Zengin N; Anatolian Society of Medical Oncology. Uncu D, et al. Among authors: buyukberber s. Oncology. 2013;84(4):240-5. doi: 10.1159/000336902. Epub 2013 Feb 7. Oncology. 2013. PMID: 23392240 Clinical Trial.
Docetaxel combined with oral etoposide as second-line treatment for advanced gastric carcinoma after failure of platinum- and fluoropyrimidine-based regimens.
Yildiz R, Kalender ME, Dane F, Sevinc A, Gumus M, Camci C, Alici S, Kaya AO, Yaman E, Ozturk B, Coskun U, Benekli M, Uncu D, Buyukberber S. Yildiz R, et al. Among authors: buyukberber s. J Oncol Pharm Pract. 2010 Sep;16(3):173-8. doi: 10.1177/1078155209347402. Epub 2009 Oct 15. J Oncol Pharm Pract. 2010. PMID: 19833685
Bevacizumab plus irinotecan in recurrent or progressive malign glioma: a multicenter study of the Anatolian Society of Medical Oncology (ASMO).
Demirci U, Tufan G, Aktas B, Balakan O, Alacacioglu A, Dane F, Engin H, Kaplan MA, Gunaydin Y, Ozdemir NY, Tugba Unek I, Karaca H, Akman T, Sonmez OU, Coskun U, Harputluoglu H, Sevinc A, Tonyali O, Buyukberber S, Benekli M. Demirci U, et al. Among authors: buyukberber s. J Cancer Res Clin Oncol. 2013 May;139(5):829-35. doi: 10.1007/s00432-013-1390-8. Epub 2013 Feb 12. J Cancer Res Clin Oncol. 2013. PMID: 23400732
Lapatinib plus capecitabine for brain metastases in patients with human epidermal growth factor receptor 2-positive advanced breast cancer: a review of the Anatolian Society of Medical Oncology (ASMO) experience.
Cetin B, Benekli M, Oksuzoglu B, Koral L, Ulas A, Dane F, Turker I, Kaplan MA, Koca D, Boruban C, Yilmaz B, Sevinc A, Berk V, Isıkdogan A, Uncu D, Harputluoglu H, Coskun U, Buyukberber S. Cetin B, et al. Among authors: buyukberber s. Onkologie. 2012;35(12):740-5. doi: 10.1159/000345040. Epub 2012 Oct 31. Onkologie. 2012. PMID: 23207619
197 results